Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Dayvigo is a prescription orexin receptor antagonist containing lemborexant. It is approved for adults with insomnia characterized by difficulty falling asleep, staying asleep, or both. Tablets come in 5 mg and 10 mg strengths. Lemborexant is a Schedule IV controlled substance in the United States.
read more about dayvigo ...Lemborexant blocks orexin receptors OX1R and OX2R. Orexin A and orexin B are neuropeptides involved in promoting wakefulness. Blocking their binding suppresses wake-related signaling, which helps patients fall asleep and stay asleep. The labeled mechanism differs from medicines that act mainly through GABA receptors.
Dayvigo is used in adults with insomnia involving sleep-onset difficulty, sleep-maintenance difficulty, or both. It is contraindicated in patients with narcolepsy. The effect on breathing is considered in patients with impaired respiratory function, including obstructive sleep apnea or chronic obstructive pulmonary disease.
The recommended dose is 5 mg no more than once per night immediately before bedtime, with at least seven hours remaining before planned awakening. The dose can increase to 10 mg according to response and tolerability. Taking Dayvigo with or soon after food can delay the time to sleep onset.
Dayvigo can impair alertness and motor coordination the next day, especially at the 10 mg dose. Other concerns include sleep paralysis, hallucinations around sleep transitions, cataplexy-like symptoms, complex sleep behaviors, worsening depression, suicidal thinking, and additive sedation with alcohol or other central nervous system depressants.
Dayvigo treats adult insomnia involving difficulty falling asleep, staying asleep, or both.
Dayvigo is taken no more than once per night immediately before bedtime.
The maximum recommended dose is 10 mg once nightly.
Yes. Lemborexant is classified as a Schedule IV controlled substance in the United States.
DailyMed - DAYVIGO (lemborexant) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7074cb65-77b3-45d2-8e8d-da8dc0f70bfd. Date Accessed September 24, 2026.
DAYVIGO (lemborexant) Prescribing Information. https://us.eisai.com/-/media/Files/DAYVIGO/PDF/prescribing-information.pdf. Date Accessed September 24, 2026.
FDA Label - DAYVIGO (lemborexant) Tablets. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212028s011lbl.pdf. Date Accessed September 24, 2026.
Lemborexant. MedlinePlus. https://medlineplus.gov/druginfo/meds/a620039.html. Date Accessed September 24, 2026.
Lemborexant. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Lemborexant. Date Accessed September 24, 2026.